Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RASSF1 CRISPR/Cas9 KO Plasmid (h): sc-401931
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RASSF1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the RASSF1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: RASSF1 Antibody (3F3): sc-58470
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RASSF1 CRISPR/Cas9 KO Plasmid (h) | sc-401931 | 20 µg | $397.00 |
Overview
RASSF1 (Ras association domain family member 1) is a scaffold protein that integrates Ras-related cues with Hippo signaling and cytoskeletal dynamics to regulate cell-cycle progression, apoptosis, and microtubule stability. Through interactions with MST1/2 and other pathway components, RASSF1 supports pro-apoptotic and growth-restraining programs that influence contact inhibition and genomic integrity. The gene is frequently epigenetically silenced via promoter hypermethylation in a broad range of tumors, making it a commonly studied tumor suppressor locus in cancer biology. Altered RASSF1 activity has also been linked to dysregulated mitotic control and stress-response signaling, with downstream effects on proliferation and cell survival phenotypes.
RASSF1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RASSF1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RASSF1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RASSF1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RASSF1 protein expression.
This CRISPR knockout system enables efficient generation of RASSF1-deficient cell models for investigation of RASSF1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RASSF1 exon(s) critical for RASSF1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RASSF1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by RASSF1 CRISPR/Cas9 KO Plasmid (h) and RASSF1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RASSF1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by RASSF1 HDR Plasmid (h) and RASSF1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RASSF1 homology arms to support homology-directed repair at defined RASSF1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.